BioNTech SE (22UA) — Cash Flow Reinvestment Rate
BioNTech SE (22UA) has a Cash Flow Reinvestment Rate of 9.66x as of December 2025, reinvesting €2.99 Billion (capex €62.10 Million plus investments €-2.93 Billion) from operating cash flow of €309.50 Million. See BioNTech SE (22UA) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
BioNTech SE Cash Flow Reinvestment Rate (2021–2025)
Historical reinvestment intensity for BioNTech SE across 5 annual periods. For the full cash flow conversion analysis, see cash flow conversion of BioNTech SE.
Annual Cash Flow Reinvestment Rate for BioNTech SE (2021–2025)
Year-by-year capital reinvestment analysis for BioNTech SE. See how financially flexible is BioNTech SE to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (EUR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 5.83x | €2.66 Billion | €456.00 Million | €749.00 Million | ▼ -41.8% |
| 2024 | 10.03x | €2.08 Billion | €207.70 Million | €452.30 Million | ▲ +713.8% |
| 2023 | 1.23x | €6.62 Billion | €5.37 Billion | €705.50 Million | ▲ +4096.5% |
| 2022 | 0.03x | €398.60 Million | €13.58 Billion | €363.30 Million | ▼ -95.0% |
| 2021 | 0.59x | €522.20 Million | €889.70 Million | €127.50 Million | — |